How one case redefined access, affordability, and the future of patents in India
When we talk about intellectual property law in India, few cases have had the kind of ripple effect that Bayer Corporation v. Natco Pharma did. It wasn’t just a legal dispute - it was a turning point that tested how far patent rights could go when public health was on the line.
In 2012, India made international headlines when the Controller General of Patents granted the country’s first-ever compulsory licence for Bayer’s cancer drug, Nexavar. For the first time, the Indian patent system was used to override a multinational’s monopoly in the interest of patients who simply couldn’t afford the medicine.
And that changed everything.
The story behind the case
Let’s rewind a bit. Bayer Corporation held a patent for sorafenib tosylate, marketed as Nexavar, a life-extending drug for kidney and liver cancer. The price? About ₹2,80,000 per month.
For most Indian patients, that number was unimaginable. Only a tiny fraction of those who needed it could afford it. Meanwhile, local manufacturers like Natco Pharma, which had the capability to make generic versions at a fraction of the price around ₹8,800 per month, were locked out because of the patent.
Natco didn’t take that quietly. It applied to the Indian Patent Office for a compulsory licence under Section 84 of the Patents Act, 1970, which allows third parties to seek permission to produce a patented product without the patent holder’s consent under specific conditions.
Those conditions are quite straightforward:
The reasonable requirements of the public aren’t being met.
The product isn’t available at an affordable price.
The patented invention isn’t being “worked” in India (in simple terms, it’s not being made or manufactured in the country).
In March 2012, the Controller agreed with Natco on all three counts—and granted the licence.
That one decision shook up global pharma boardrooms.
What the Controller found
The Patent Controller’s reasoning was methodical. Bayer was importing only small quantities of Nexavar, enough for a few hundred patients each year, when thousands needed it. The drug’s price made it accessible to less than 2% of the patient pool.
On “working of the patent,” Bayer’s defence was that importing the drug from Germany amounted to “working” in India. The Controller disagreed. For a patent to be “worked,” the technology should ideally be put into practical use within the country - through manufacturing or local availability at reasonable scale and cost. Simply importing a few batches wasn’t good enough.
On affordability, the difference was stark. ₹2.8 lakh versus ₹8,800. That wasn’t just a price gap - it was a moral gap.
The order directed Natco to pay a 6% royalty to Bayer on its net sales of the drug and required Natco to sell it only in India, with proper packaging and quality controls.
Later, when Bayer appealed to the Intellectual Property Appellate Board (IPAB), the decision was largely upheld, with a minor tweak: the royalty was raised from 6% to 7%.
Why this case mattered
Before this case, the concept of compulsory licensing in India was largely theoretical. It existed in the law but had never been tested. After the Natco licence, it became a precedent -a message that India would prioritize access over absolute exclusivity when public health was at stake.
It also forced global pharma companies to rethink their India strategies. The ruling made it clear that patent rights in India are not unconditional; they come with responsibilities - especially when the invention addresses life-saving needs.
From a broader policy angle, this case balanced two pillars: innovation and public interest. While patents reward innovation, they cannot exist in isolation from the realities of affordability and availability, especially in a country where healthcare costs push millions into poverty every year.
Understanding Section 84 - in plain English
Section 84 is the backbone of compulsory licensing in India. Think of it as a built-in safety valve in the patent system.
It says that any person (after three years from the grant of a patent) can apply for a compulsory licence if:
The reasonable requirements of the public aren’t being met,
The invention isn’t available at a reasonably affordable price, or
The invention isn’t being “worked” in India.
The key word is reasonable - a deliberately flexible term that allows the Controller to weigh market realities, access, and fairness.
The provision doesn’t take away the patent holder’s rights; it simply ensures that those rights serve a broader public purpose.
Lessons for patent owners
If you’re a patent holder, especially in pharmaceuticals or biotechnology, the Bayer–Natco case is a masterclass in what not to overlook.
Here are a few takeaways worth keeping in mind:
Ensure local working of your patent.
Don’t rely solely on imports. If manufacturing locally isn’t feasible, document why - show technology transfer efforts, contract manufacturing arrangements, or partnerships.Price strategically.
Indian law doesn’t expect you to give away your product, but “reasonably affordable” is the benchmark. Offer voluntary licences or tiered pricing models before you’re forced to grant one.Maintain records that show supply adequacy.
If you’re meeting patient demand, have the numbers ready - sales data, distribution reach, and local partnerships.Proactive engagement helps.
Many compulsory licence applications can be avoided if patentees engage with the government and local partners early.
Bayer’s experience shows that ignoring market signals can be far costlier than collaborating with them.
Lessons for generic manufacturers and startups
If you’re a manufacturer or a biotech startup eyeing a patented technology, this case also offers a roadmap.
Natco didn’t just walk into the Patent Office and ask for a licence - it built a strong, evidence-backed case. Here’s what worked in its favour:
It presented data on public demand and pricing gaps.
It showed manufacturing capability and readiness to scale.
It proposed a reasonable royalty and undertook to follow strict quality norms.
In other words, it came prepared with a credible business plan, not just a complaint.
For startups exploring similar routes -say, in medical devices, green tech, or essential utilities - the same logic applies: bring data, show capacity, and demonstrate genuine public interest.
Business and policy impact
Beyond the courtroom, this case triggered wider discussions about India’s role as the “pharmacy of the developing world.”
The Natco licence didn’t just make Nexavar cheaper - it sent a signal that India’s patent system could flex to serve both innovation and humanity.
For multinational companies, it was a wake-up call to adapt their global pricing models to local economies. For Indian pharma, it was validation that the law could support responsible access to affordable medicines.
Even the World Trade Organization’s TRIPS Agreement allows compulsory licensing as a legitimate flexibility, and India used that space judiciously.
The road since then
Interestingly, while this case opened the door, it didn’t flood the system with compulsory licence applications.
Why? Because the message was clear: the law is not anti-patent -it’s pro-balance. Companies learned to adjust. Many began offering voluntary licences to Indian firms, ensuring access without litigation.
The government, too, exercised restraint. Compulsory licensing remained the exception, not the rule, preserving India’s credibility as a TRIPS-compliant jurisdiction that respects both patents and public interest.
Understanding the royalty question
One of the most debated aspects was the royalty rate. Natco initially offered 6%, which the Controller accepted. Bayer argued it was too low.
When the IPAB revisited the case, it raised the rate slightly to 7%, citing international benchmarks and the need to balance access with fair compensation.
That’s important for future applicants - royalty isn’t an afterthought; it’s a key piece of evidence that shows fairness and respect for innovation, even while seeking access.
What this means for you
If you’re a pharma company, startup, or inventor—this case isn’t just history; it’s a guidepost.
For patentees, it’s a reminder that the right strategy involves not just securing protection but also aligning it with market and social realities. For generic companies, it’s proof that with the right preparation, the law provides avenues to expand access responsibly.
For investors and business leaders, it highlights that IP isn’t just a legal shield—it’s a business lever. How you manage it determines whether it protects your market or exposes you to regulatory challenges.
A practical takeaway: when to seek advice
Many inventors and businesses only think about IP strategy after a dispute arises. But as Bayer and Natco showed, what happens before litigation often decides its outcome.
If you hold patents in India - especially in critical sectors like healthcare, energy, or agriculture - it’s worth reviewing whether they’re being worked, how pricing aligns with market expectations, and whether documentation supports public benefit.
And if you’re considering applying for a compulsory licence, timing and preparation are everything. Get your data in order, consult a patent professional, and structure your evidence carefully.
That’s where firms like ours step in - to bridge the gap between law, strategy, and market execution.
Closing thought
Looking back, the Bayer v. Natco case was never just about a drug. It was about the soul of patent law - its purpose and its boundaries.
India didn’t reject patents; it reaffirmed that innovation serves its highest purpose when it reaches the people who need it most.
And that balance - between exclusivity and equity - is what makes the Indian patent system both complex and beautifully human.
